Sonata Related Published Studies
Well-designed clinical trials related to Sonata (Zaleplon)
Zaleplon and zolpidem objectively alleviate sleep disturbances in mountaineers at a 3,613 meter altitude. [2007.11.01]
Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening. [2006.10.15]
High-performance liquid chromatography-atmospheric pressure chemical ionisation-mass spectrometry determination of zaleplon in human plasma. [2006.02.24]
Zaleplon (Sonata) oral sedation for outpatient third molar extraction surgery. [2005.01]
Sleep-inducing pharmaceuticals: a comparison of melatonin, zaleplon, zopiclone, and temazepam. [2004.06]
Effects of zolpidem and zaleplon on sleep, respiratory patterns and performance at a simulated altitude of 4,000 m. [2004]
Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. [2003.12]
Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg. [2003.07]
Zaleplon improves sleep quality in maintenance hemodialysis patients. [2003]
Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. [2002.03.15]
Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. [2000.12]
Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. [2000.08]
Absence of an interaction between ibuprofen and zaleplon. [2000.06.15]
Psychomotor effects of zaleplon and thioridazine coadministration. [2000.06]
Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. [2000.06]
Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. [2000.05]
Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. [2000.01]
A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. [1999.09]
Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. [1999.08]
Zaleplon pharmacokinetics and absolute bioavailability. [1999.04]
Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. [1998.11]
Well-designed clinical trials possibly related to Sonata (Zaleplon)
Hypnotic discontinuation in chronic insomnia: impact of psychological distress, readiness to change, and self-efficacy. [2008.03]
Angiotensin II decreases the renal MRI blood oxygenation level-dependent signal. [2006.06]
Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. [2006.01]
Long-term use of sedative hypnotics in older patients with insomnia. [2005.03]
The acute effect of music on interictal epileptiform discharges. [2004.10]
"A comparison of the effectiveness of two hypnotic agents for the treatment of insomnia". [2004.08]
Is listening to Mozart the only way to enhance spatial reasoning? [2003.12]
The Mozart effect may only be demonstrable in nonmusicians. [2002.12]
Efficacy of L-846 in patients with insomnia: evaluation by polysomnography. [1998.04]
Listening to Mozart may not enhance performance on the revised Minnesota Paper Form Board Test. [1995.08]
A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic. [1994.04]
The effects of single doses of CL284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers. [1993]
Other research related to Sonata (Zaleplon)
[Side effects after the usage of Chinese dieting product Meizitanc] [2007]
Usefulness of temazepam and zaleplon to induce afternoon sleep. [2006.10]
Comparison of zolpidem and zaleplon exposures in Texas, 1998-2004. [2006.10]
Benefit-risk assessment of zaleplon in the treatment of insomnia. [2005]
Hypnotic efficacy of zaleplon for daytime sleep in rested individuals. [2004.08.01]
Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats. [2004.03]
Performance following a sudden awakening from daytime nap induced by zaleplon. [2004.01]
Mixed drug intoxication involving zaleplon ("Sonata"). [2003.07.08]
Zaleplon and driving impairment. [2003.05]
Clinically important drug interactions with zopiclone, zolpidem and zaleplon. [2003]
New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. [2003]
Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. [2002.12]
Safety of zaleplon in the treatment of insomnia. [2002.05]
Management of insomnia--the role of zaleplon. [2002.03.14]
Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon. [2002.02]
Changes in GABA(A) receptor gene expression induced by withdrawal of, but not by long-term exposure to, zaleplon or zolpidem. [2002.02]
Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent. [2001.07]
Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening. [2001.03]
Efficacy and safety of zaleplon at peak plasma levels. [2001.01]
Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. [2000.12.22]
Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia. [2000.12]
Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia. [2000.11]
Zaleplon: a review of its use in the treatment of insomnia. [2000.08]
Zaleplon - a review of a novel sedative hypnotic used in the treatment of insomnia. [2000.04]
Zaleplon, A Novel Nonbenzodiazepine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound Effects. [1999.08]
[Pharma-clinics. Drug of the month. Zaleplon (Sonata)] [1999.08]
Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. [1999.07]
Rapid disappearance of zaleplon from breast milk after oral administration to lactating women. [1999.07]
Other possibly related research studies
Eszopiclone (Lunesta): a new nonbenzodiazepine hypnotic agent. [2006.01]
Planimetry of aortic valve area in aortic stenosis by magnetic resonance imaging. [2005.10]
[MR angiography and determination of the flow reserve after minimal invasive direct coronary artery bypass (MIDCAB) surgery of the left internal mammary artery in comparison to multirow CT] [2005.08]
Fatigue in military aviation: an overview of US military-approved pharmacological countermeasures. [2005.07]
Dose optimization of contrast-enhanced carotid MR angiography. [2005.09]
High-resolution three-dimensional T2-weighted sequence for neuronavigation: a new setup and clinical trial. [2005.04]
[Contribution of early systole to total antegrade flow volume in breath-hold phase-contrast flow measurements] [2005.05]
Early regional assessment of LV mass regression and function after stentless valve replacement: comparative randomized study. [2004]
Diagnosis and treatment of chronic insomnia: a review. [2005.03]
Feasibility of MR-guided angioplasty of femoral artery stenoses using real-time imaging and intraarterial contrast-enhanced MR angiography. [2004.09]
The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. [2004]
Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. [2004.07]
[Determining myocardial viability in myocardial infarct. Comparison of single and multisclice MRI techniques with TurboFlash and TrueFISP sequences] [2004.02]
Time-resolved magnetic resonance angiography as a noninvasive method to characterize endoleaks: initial results compared with conventional angiography. [2004.01]
[Drug treatment of sleep disorders in the elderly] [2003.09]
MRI atlas of the human cerebellar nuclei. [2002.09]
Selective actions on sleep or anxiety by exploiting GABA-A/benzodiazepine receptor subtypes. [2002.03]
0.5 M Gd chelate (Magnevist) versus 1.0 M Gd chelate (Gadovist): dose-independent effect on image quality of pelvic three-dimensional MR-angiography. [2001.11]
Pyrazolopyrimidines. [2001.11.10]
Chinrest pressure in violin playing: type of music, chin rest, and shoulder pad as possible mediators. [1997.04]
Consequences of insomnia and its therapies. [2001]
A psychiatric perspective on insomnia. [2001]
A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France. [2001.01]
The relationship between psychiatric diseases and insomnia. [2001.01]
Individualizing therapy for early, middle-of-the-night and late-night insomnia. [2001.01]
Implications of hypnotic flexibility on patterns of clinical use. [2001.01]
Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. [1998.06]
[Recent progress in development of hypnotic drugs] [1998.02]
Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. [2005.11.19]
Eszopiclone for insomnia. [2005.10]
Diagnosis and management of insomnia in older people. [2005.07]
Examination of antimicrobial activity of selected non-antibiotic drugs. [2004.12]
Contribution of alpha 1GABAA and alpha 5GABAA receptor subtypes to the discriminative stimulus effects of ethanol in squirrel monkeys. [2005.05]
Residual effects of sleep medication on driving ability. [2004.08]
Treatment of primary insomnia. [2004.05]
Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. [2004.06]
Residual effects of hypnotics: epidemiology and clinical implications. [2004]
Ziprasidone metabolism, aldehyde oxidase, and clinical implications. [2003.06]
Differential effects in humans after repeated administrations of zolpidem and triazolam. [2003.05]
Efficacy, safety and cost of new drugs acting on the central nervous system. [2003.05]
|
